Carlson Capital Management Has $2.29 Million Holdings in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Carlson Capital Management cut its holdings in Johnson & Johnson (NYSE:JNJ) by 2.1% during the 1st quarter, HoldingsChannel reports. The fund owned 13,915 shares of the company’s stock after selling 298 shares during the quarter. Johnson & Johnson accounts for approximately 0.4% of Carlson Capital Management’s holdings, making the stock its 26th largest position. Carlson Capital Management’s holdings in Johnson & Johnson were worth $2,287,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Essex Investment Management Co. LLC grew its stake in shares of Johnson & Johnson by 95.5% in the fourth quarter. Essex Investment Management Co. LLC now owns 481 shares of the company’s stock valued at $76,000 after acquiring an additional 235 shares in the last quarter. WoodTrust Financial Corp grew its stake in Johnson & Johnson by 36.5% during the fourth quarter. WoodTrust Financial Corp now owns 62,545 shares of the company’s stock worth $9,843,000 after buying an additional 16,723 shares in the last quarter. TCTC Holdings LLC grew its stake in Johnson & Johnson by 5.8% during the fourth quarter. TCTC Holdings LLC now owns 68,014 shares of the company’s stock worth $10,704,000 after buying an additional 3,743 shares in the last quarter. FCA Corp TX grew its stake in Johnson & Johnson by 13.8% during the fourth quarter. FCA Corp TX now owns 21,315 shares of the company’s stock worth $3,354,000 after buying an additional 2,584 shares in the last quarter. Finally, Balasa Dinverno & Foltz LLC grew its stake in Johnson & Johnson by 22.1% during the fourth quarter. Balasa Dinverno & Foltz LLC now owns 37,648 shares of the company’s stock worth $5,925,000 after buying an additional 6,812 shares in the last quarter. Institutional investors and hedge funds own 67.25% of the company’s stock.

JNJ has been the topic of a number of analyst reports. Credit Suisse Group increased their price objective on shares of Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $178.00 to $187.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 27th. Cowen raised their price target on shares of Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a research note on Wednesday, January 27th. Wells Fargo & Company raised their price objective on shares of Johnson & Johnson from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Wednesday, January 27th. Finally, Cantor Fitzgerald raised their price objective on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, January 26th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $178.60.

Shares of NYSE JNJ opened at $161.64 on Tuesday. The firm has a market capitalization of $425.55 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 3.06 and a beta of 0.70. The business has a 50-day moving average of $160.81 and a 200-day moving average of $154.79. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 12 month low of $133.65 and a 12 month high of $173.65.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Monday, January 25th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.82 by $0.04. The business had revenue of $22.50 million during the quarter, compared to analyst estimates of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.88 earnings per share. On average, analysts predict that Johnson & Johnson will post 7.99 earnings per share for the current year.

Johnson & Johnson Profile

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More: What is the CAC 40 Index?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.